Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015, Article ID 265786, 4 pages
http://dx.doi.org/10.1155/2015/265786
Case Report

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

1Department of Oncology, ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
2Department of Medical Endocrinology, ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
3Department of Clinical Genetics, ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
4Department of Cardiothoracic Surgery, ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
5Department of Pathology, ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
6Department of Surgical Gastroenterology, ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark

Received 6 September 2015; Accepted 16 December 2015

Academic Editor: Tobias Keck

Copyright © 2015 Seppo W. Langer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Pilarski, “Cowden syndrome: a critical review of the clinical literature,” Journal of Genetic Counseling, vol. 18, no. 1, pp. 13–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Gustafson, K. M. Zbuk, C. Scacheri, and C. Eng, “Cowden syndrome,” Seminars in Oncology, vol. 34, no. 5, pp. 428–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ngeow, J. Mester, L. A. Rybicki, Y. Ni, M. Milas, and C. Eng, “Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with cowden and cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 12, pp. E2063–E2071, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Pilarski, R. Burt, W. Kohlman, L. Pho, K. M. Shannon, and E. Swisher, “Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria,” Journal of the National Cancer Institute, vol. 105, no. 21, pp. 1607–1616, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/familial high-risk assessment: Breast and Ovarian Version 2. 2015, http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
  6. J. W. Trufant, L. Greene, D. L. Cook, W. McKinnon, M. Greenblatt, and M. W. Bosenberg, “Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: a case report and literature review,” Human Pathology, vol. 43, no. 4, pp. 601–604, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Kalhor, S. Suster, and C. A. Moran, “Pathology,” in Neuroendocrine Tumors, J. C. Yao, P. M. Hoff, and A. O. Hoff, Eds., Springer, New York, NY, USA, 2011. View at Google Scholar
  8. J. C. Yao, M. Hassan, A. Phan et al., “One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Rindi, C. Klersy, F. Inzani et al., “Grading the neuroendocrine tumors of the lung: an evidence-based proposal,” Endocrine-Related Cancer, vol. 21, no. 1, pp. 1–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. I. Gustafsson, M. Kidd, and I. M. Modlin, “Broncho-pulmonary carcinoid tumors,” in A Century of Advances in Neuroendocrine Tumor Biology and Treatment, I. M. Modlin and K. Öberg, Eds., pp. 54–65, 2007. View at Google Scholar
  11. J. Mester and C. Eng, “Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome,” Genetics in Medicine, vol. 14, no. 9, pp. 819–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. H. Nieuwenhuis, C. M. Kets, M. Murphy-Ryan et al., “Is colorectal surveillance indicated in patients with PTEN mutations?” Colorectal Disease, vol. 14, no. 9, pp. e562–e566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. F. C. Detterbeck, “Management of carcinoid tumors,” Annals of Thoracic Surgery, vol. 89, no. 3, pp. 998–1005, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Lawrence, B. I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, and I. M. Modlin, “The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors,” Endocrinology and Metabolism Clinics of North America, vol. 40, no. 1, pp. 111–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. B. Lodish and C. A. Stratakis, “Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 24, no. 3, pp. 439–449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. R. Nelen, W. C. G. van Staveren, E. A. J. Peeters et al., “Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease,” Human Molecular Genetics, vol. 6, no. 8, pp. 1383–1387, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Inoki, M. N. Corradetti, and K.-L. Guan, “Dysregulation of the TSC-mTOR pathway in human disease,” Nature Genetics, vol. 37, no. 1, pp. 19–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. H. Squarize, R. M. Castilho, and J. S. Gutkind, “Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin,” Cancer Research, vol. 68, no. 17, pp. 7066–7072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. B. Johnbeck, M. M. Jensen, C. H. Nielsen, A. M. F. Hag, U. Knigge, and A. Kjaer, “18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice,” PLoS ONE, vol. 9, no. 3, Article ID e91387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Zatelli, M. Minoia, C. Martini et al., “Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids,” Endocrine-Related Cancer, vol. 17, no. 3, pp. 719–729, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Fazio, D. Granberg, A. Grossman et al., “Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study,” Chest, vol. 143, no. 4, pp. 955–962, 2013. View at Publisher · View at Google Scholar · View at Scopus